For women with in situ breast disease, the 313-single nucleotide polymorphism breast cancer polygenic risk score (PRS313) can predict the likelihood of developing future breast cancer.
Prophylactic radiation therapy to the contralateral breast significantly delayed the onset of contralateral breast cancer in carriers of BRCA1/2 pathogenic variants with early breast cancer. The ...
Abemaciclib plus endocrine therapy significantly improved overall survival, IDFS, and DRFS in HR-positive, HER2-negative, node-positive early breast cancer. Adjuvant abemaciclib (Verzenio; Eli Lilly) ...
17don MSN
A polygenic risk score may predict future breast cancer in patients with early-stage diagnoses
A retrospective study found that the 313-SNP breast cancer polygenic risk score (PRS313) blood test could predict future incidents of breast cancer in women diagnosed with ductal carcinoma in situ ...
A polygenetic risk score can predict which women with in situ breast cancer will develop invasive disease and guide clinical ...
An increased risk of local-regional recurrence in stage 1 non–small cell lung cancer (NSCLC) was found in individuals who needed a percutaneous transthoracic needle biopsy (PTNB) prior to their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback